Magdalena biosciences, a joint venture between jaguar health and filament health, receives second tranche of funding from one small planet

Magdalena biosciences, a joint venture recently formed by jaguar health and filament health corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications san francisco, ca / accesswire / october 30, 2023 / jaguar health, inc. (nasdaq:jagx) today announced that magdalena biosciences, inc. (magdalena), the joint venture recently formed by jaguar and filament health corp. (otcqb:flhlf) (neo:fh) (fse:7qs) to develop novel, natural prescription medicines derived from plants for mental health indications such as depression, anxiety, attention-deficit/hyperactivity disorder (adhd) and other possible neuropsychiatric conditions initially in adults, has received the second tranche of funding from one small planet. as announced, boulder, colorado-based one small planet, founded by will peterffy, committed to initial funding of us$1,000,000 for magdalena, with the funds payable in quarterly installments in 2023 based on the achievement of defined milestones by magdalena.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score